- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03938792
Estudo da Eficácia e Segurança PF-06741086 em Participantes Adultos e Adolescentes com Hemofilia A Grave ou Hemofilia B Moderadamente Grave a Grave
Um estudo aberto em adolescentes e adultos graves (atividade do fator de coagulação
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Jeddah, Arábia Saudita, 21589
- King AbdulAziz University Hospital
-
Riyadh, Arábia Saudita
- King Faisal Specialist Hospital & Research Center
-
-
-
-
-
Sofia, Bulgária, 1756
- National Specialized Hospital for the Active Treatment of Hematological Diseases - EAD, Sofia
-
Stara Zagora, Bulgária, 6003
- UMHAT "Prof.Dr. Stoyan Kirkovich"
-
-
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8S 4K1
- McMaster University
-
Hamilton, Ontario, Canadá, L8S 4K1
- McMaster Children's Hospital
-
Hamilton, Ontario, Canadá, L8N 3Z5
- McMaster University Medical Centre - Hamilton Health Sciences
-
Toronto, Ontario, Canadá, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Beijing, China, 100045
- Beijing Children's Hospital, Capital Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510515
- Nanfang Hospital, Southern Medical University
-
-
Guizhou
-
Guiyang, Guizhou, China, 550004
- The Affiliated Hospital of Guizhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 306113
- Jiangxi Provincial People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300020
- Institute of Hematology, Chinese Academy of Medical Sciences
-
-
-
-
-
Daegu, Coréia do Sul, 41944
- Kyungpook National University Hospital
-
Seoul, Coréia do Sul, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Coréia do Sul, 05278
- Kyung Hee University Hospital at Gangdong
-
-
-
-
-
Zagreb, Croácia, 10000
- Klinicki bolnicki centar Zagreb
-
-
-
-
-
A Coruña, Espanha, 15006
- Hospital Universitario A Coruna
-
Barcelona, Espanha, 08035
- Hospital Universitario Vall d´Hebron
-
Madrid, Espanha, 28046
- Hospital Universitario La Paz
-
Salamanca, Espanha, 37007
- Hospital Universitario De Salamanca
-
Zaragoza, Espanha, 50009
- Hospital Universitario Miguel Servet
-
-
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- USF Health Morsani Center for Advanced Healthcare
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa
-
-
New York
-
New Hyde Park, New York, Estados Unidos, 11040
- Northwell Health HTC
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98101
- Washington Institute for Coagulation
-
-
-
-
-
Paris, França, 75015
- Hôpital Necker Enfants malades
-
-
-
-
-
Hong Kong, Hong Kong
- Queen Mary Hospital
-
Hong Kong, Hong Kong
- Prince of Wales Hospital
-
-
-
-
-
Perugia, Itália, 06156
- Università degli Studi di Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria della
-
-
Milan
-
Milan, Milan, Itália, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
-
RM
-
Roma, RM, Itália, 00161
- Università degli Studi di Roma "Sapienza"-Policlinico Umberto I
-
-
-
-
-
Hiroshima, Japão, 734-8551
- Hiroshima University Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japão, 466-8560
- Nagoya University Hospital - Transfusion Medicine
-
-
Hokkaido
-
Sapporo, Hokkaido, Japão, 004-0041
- Sapporo Tokushukai Hospital
-
-
Saitama
-
Iruma-gun, Saitama, Japão, 350-0495
- Saitama Medical University Hospital
-
-
-
-
Nuevo León
-
Monterrey, Nuevo León, México, 64460
- Hospital Universitario "Dr Jose Eleuterio Gonzalez"
-
-
Yucatán
-
Mérida, Yucatán, México, 97130
- Centro Multidisciplinario para el Desarrollo Especializado de la Inv. Clínica en Yucatán, S.C.P.
-
-
-
-
-
Muscat, Omã, 123
- Sultan Qaboos University Hospital
-
-
-
-
-
Samara, Rússia, 443079
- FGBOU VO "Samara State Medical University" of MoH of Russia
-
-
-
-
-
Belgrade, Sérvia, 11000
- Clinical Center of Serbia
-
Belgrade, Sérvia, 11000
- Institute for Mother and Child healthcare "Dr Vukan Cupic"
-
Kragujevac, Sérvia, 34000
- Clinical Center Kragujevac
-
Niš, Sérvia, 18000
- Clinical Center Niš
-
-
-
-
-
Taichung, Taiwan, 40705
- Taichung Veterans General Hospital
-
-
Changhua County
-
Changhua, Changhua County, Taiwan, 500
- Changhua Christian Hospital
-
-
-
-
-
Adana, Turquia (Türkiye), 01130
- Acibadem Adana Hospital
-
Ankara, Turquia (Türkiye), 06230
- Hacettepe University Medical Faculty
-
Ankara, Turquia (Türkiye), 06500
- Gazi University Health Research and Practice Center Gazi Hospital
-
Antalya, Turquia (Türkiye), 07060
- Akdeniz University Medical Faculty
-
Gaziantep, Turquia (Türkiye), 27310
- Gaziantep University Sahinbey Research and Training Hospital
-
Istanbul, Turquia (Türkiye), 34093
- Istanbul University Oncology Institute
-
Izmir, Turquia (Türkiye), 35040
- Ege University Medical Faculty
-
Izmir, Turquia (Türkiye), 35210
- Dr. Behcet Uz Child Diseases Surgery Education and Research Hospital
-
Kayseri, Turquia (Türkiye), 38039
- Erciyes University Medical Faculty
-
Samsun, Turquia (Türkiye), 55280
- Ondokuz Mayıs University Medical Faculty
-
Trabzon, Turquia (Türkiye), 61080
- Karadeniz Technical University Medical Faculty
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, África do Sul, 2193
- Charlotte Maxeke Johannesburg Academic Hospital
-
-
-
-
Gujarat
-
Surat, Gujarat, Índia, 395002
- Nirmal Hospital Pvt, Ltd
-
-
Maharashtra
-
Pune, Maharashtra, Índia, 411004
- Sahyadri Super Speciality Hospital
-
Pune, Maharashtra, Índia, 411004
- Sahyadri Clinical Research And Development Center
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Índia, 632004
- Christian Medical College
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Descrição
Critério de inclusão
- Participantes com diagnóstico de hemofilia A grave ou hemofilia B moderadamente grave a grave com peso mínimo de 35 kg na triagem.
- Participante ou representante legalmente autorizado, ou cuidador do participante capaz de dar consentimento informado assinado (ou consentimento menor, quando aplicável).
Os participantes inscritos na Coorte de Não Inibidores também devem atender aos seguintes critérios:
- Sem histórico detectável ou documentado de inibidores
- Participantes em profilaxia de rotina FVIII/FIX que demonstraram pelo menos 80% de adesão ao regime de profilaxia programado durante 6 meses antes da inscrição e estão dispostos a continuar a receber tratamento profilático de rotina com substituição de FVIII/FIX durante a Fase de Observação.
- Participantes com regime de tratamento sob demanda com ≥6 episódios hemorrágicos agudos (espontâneos ou traumáticos) que necessitaram de infusão de fator de coagulação durante o período de 6 meses antes da inscrição e dispostos a continuar a receber tratamento sob demanda durante a Fase de Observação.
Os participantes inscritos na Coorte de Inibidores também devem atender aos seguintes critérios:
- Documentação de inibidor de título alto atual (≥5 BU/mL) ou inibidor de título baixo atual (<5 BU/mL) refratário à substituição de FVIII ou FIX e com recuperação de FVIII ou FIX <60% do esperado nos 6 meses anteriores à inscrição no a Fase Observacional
- Participantes de hemofilia A com regime de tratamento sob demanda com ≥6 episódios hemorrágicos ou participantes de hemofilia B com ≥4 episódios hemorrágicos (espontâneos ou traumáticos) necessitando de tratamento com fator de bypass durante os 6 meses anteriores à inscrição na fase de observação e dispostos a continuar a receber em -demanda tratamento durante a Fase Observacional.
- Participantes que documentaram inibidores durante a terapia de reposição de fator, mas que não atendem aos critérios de inibidores quantitativos descritos no item anterior no momento da triagem (por exemplo, participante com um inibidor de alto título previamente documentado (≥5 BU/mL) e cuja condição impeça a reintrodução com substituição de FVIII ou FIX) pode ser considerada elegível caso a caso com acordo prévio do Pfizer Medical Monitor
- Os participantes que atendem aos critérios de sangramento mencionados acima e que estão em profilaxia de rotina (definida como tratamento por injeção IV de fator de bypass para prevenir sangramento) e demonstraram pelo menos 80% de adesão ao regime de profilaxia programada durante os 6 meses anteriores à inscrição, podem ser considerados para elegibilidade caso a caso, com discussão e concordância do monitor médico da Pfizer.
Critério de exclusão
- Tratamento anterior ou atual para e/ou histórico de doenças das artérias coronárias, trombose venosa ou arterial ou doença isquêmica
- Procedimento cirúrgico planejado conhecido durante o período planejado do estudo.
- Defeito hemostático conhecido, exceto hemofilia A ou B.
- Função renal ou hepática anormal
- Doença hepática ou biliar instável atual
- Parâmetros hematológicos anormais
- Outra condição médica ou psiquiátrica aguda ou crônica ou anormalidade laboratorial que pode aumentar o risco associado à participação no estudo ou administração do produto experimental ou pode interferir na interpretação dos resultados do estudo e, no julgamento do investigador,
- A profilaxia de rotina atual com agente de bypass ou terapia de não reposição de fator não coagulante, ou qualquer tratamento anterior com um produto de terapia gênica para tratamento de hemofilia (participantes tratados com profilaxia usando agentes de bypass ou que tiveram tratamento anterior com produtos de não fator podem ser considerado caso a caso).
Terapia concomitante regular com drogas imunomoduladoras
- Uso contínuo ou planejado de indução de tolerância imunológica durante a Fase Observacional ou Fase de Tratamento Ativo, ou profilaxia com substituição de FVIII ou FIX a qualquer momento após o início do tratamento com intervenção do estudo durante a Fase de Tratamento Ativo
- Exposição anterior ao PF 06741086 durante a participação nos estudos B7841002 e B7841003.
- Participação em outros estudos envolvendo drogas ou vacinas experimentais dentro de 30 dias (ou conforme determinado pelos requisitos locais) ou 5 meias-vidas antes da entrada no estudo e/ou durante a participação no estudo.
- Contagem de células CD4 ≤200/uL se o vírus da imunodeficiência humana (HIV) for positivo
- Triagem de ECG que demonstra anormalidades clinicamente relevantes que podem afetar a segurança do participante ou a interpretação dos resultados do estudo.
- Indivíduos com hipersensibilidade ou reação alérgica à proteína de hamster ou outros componentes da intervenção do estudo.
- Membros da equipe do centro do investigador diretamente envolvidos na condução do estudo e seus familiares, membros da equipe do centro supervisionados pelo investigador ou participantes que sejam funcionários da Pfizer, incluindo seus familiares, diretamente envolvidos na condução do estudo.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: PF-06741086
Os participantes serão encaminhados para tratamento com PF-06741086 após uma Fase de Observação de 6 meses em seu atual regime de hemofilia.
|
Dose de ataque de 300 miligramas (mg) subcutâneo (sc) seguida de 150 mg sq uma vez por semana (qw).
300 mg sc qw é prescrito para participantes que atendem aos critérios de escalonamento de dose.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With RP at OP)
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Number of Participants With Adverse Events (AEs): Inhibitor and Non-Inhibitor Cohort
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
AEs included both serious AEs and all other AEs.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Serious Adverse Events (SAEs): Inhibitor and Non-Inhibitor Cohort
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
AE: any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
SAE: any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Thrombotic Events: Inhibitor and Non-Inhibitor Cohort
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Thrombotic events are when a blood clot (thrombus) forms in a blood vessel in the arm, leg, lung, or head and can be life-threatening.
A thrombus can occur in veins (venous thrombosis) or arteries (arterial thrombosis).
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Thrombotic Microangiopathy: Inhibitor and Non-Inhibitor Cohort
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Thrombotic microangiopathy: pathological state where micro-vessels are occluded by platelet rich thrombi leading to thrombocytopenia (low platelets) and microangiopathic haemolytic anaemia (red blood cell destruction) and potential end organ damage.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Disseminated Intravascular Coagulation/ Consumption Coagulopathy: Inhibitor and Non-Inhibitor Cohort
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Disseminated intravascular coagulation is characterized by widespread clotting in small blood vessels, and consumption of platelets and clotting factors by the clots, leading to bleeding.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF- 06741086: Inhibitor and Non-Inhibitor Cohort
Prazo: During prophylaxis treatment in ATP (12 months)
|
ADA positive: A participant with >=1 treatment induced or treatment-boosted ADA response.
NAb positive: An ADA positive participant with >=1 treatment induced or treatment boosted NAb response.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Transient and Persistent ADA and NAb Against PF-06741086: Inhibitor and Non-Inhibitor Cohort
Prazo: During prophylaxis treatment in ATP (12 months)
|
Persistent ADA: participant with treatment-induced or treatment-boosted ADA detected at 2 or more times during treatment including any follow-up, where first and last ADA positive samples separated by >=16 weeks.
Transient ADA: treatment-induced or treatment-boosted ADA detected at only 1 time during treatment or follow-up.
Persistent NAb: NAb-positive participant with first and last positive NAb samples detected >=16 weeks posttreatment, irrespective of any negative samples in between.
Transient NAb: NAb-positive participant with (1) treatment-induced/treatment-boosted NAb sample detected at only 1 time posttreatment or (2) treatment-induced/treatment-boosted NAb samples detected at 2 or more times where first and last positive samples separated by <16 weeks, and participant's last sample was NAb or ADA negative.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Injection Site Reactions (ISRs): Inhibitor and Non-Inhibitor Cohort
Prazo: During prophylaxis treatment in ATP (12 months)
|
ISR included: injection site haematoma, injection site pain, injection site bruising, injection site erythema, injection site induration, injection site oedema, Injection site pruritus and Injection site swelling.
ISR graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 where grade 1: tenderness with or without associated symptoms (warmth, erythema, itching), grade 2: pain, lipodystrophy, edema, phlebitis, grade 3: ulceration or necrosis, severe tissue damage, operative intervention indicated, grade 4: life-threatening consequences, urgent intervention indicated and grade 5: death.
In this outcome measure only categories with non-zero values reported.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Clinically Significant Changes in Physical Examinations: Inhibitor and Non-Inhibitor Cohort
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Physical examination included assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.
Height and weight were also measured and recorded.
Clinical significance in physical examinations was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Clinically Significant Changes in Vital Signs: Inhibitor and Non-Inhibitor Cohort
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Vital signs included temperature, pulse rate, respiratory rate, and blood pressure.
Blood pressure and pulse rate were measured in a supine position using completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions.
Respiratory rate was measured by observing and counting the respirations of the participant for 30 seconds and multiplied by 2. Clinical significance of vital signs was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters: Inhibitor and Non-Inhibitor Cohort
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Hematology included: hemoglobin; leukocytes; neutrophils; and platelets.
Chemistry included: potassium; aspartate aminotransferase; creatinine; alkaline phosphatase; total bilirubin; albumin; calcium corrected, estimated decreased; sodium; and calcium.
Clinical significance of laboratory parameters was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Severe/ Systematic Hypersensitivity and Anaphylactic Reactions: Inhibitor and Non-Inhibitor Cohort
Prazo: During prophylaxis treatment in ATP (12 months)
|
Systemic hypersensitivity is a complex immune response where the immune system reacts excessively to an antigen, often leading to severe allergic reactions, including widespread symptoms (which may affect multiple organs), such as rash, swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, dizziness, fainting, fast heartbeat, pounding in your chest or sweating.
Anaphylaxis is a severe, potentially fatal, systemic allergic reaction that occurs suddenly after contact with an allergy causing substance.
|
During prophylaxis treatment in ATP (12 months)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Model-Based ABR of Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of the following: pain or an unusual sensation in the joint, palpable swelling, and warmth of the skin over the joint.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Spontaneous Bleeds: Inhibitor and Non-Inhibitor Cohort
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as the number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, the days on treatment ended at the last dosing date + 6 days.
Spontaneous bleed: Bleeding for no apparent/known reason particularly into the joints, muscles, and soft tissues.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Target Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Target joint: a major joint into which repeated bleeds occurred.
Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of following: pain or unusual sensation in joint, palpable swelling, and warmth of the skin over joint.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Total Bleeds: Inhibitor and Non-Inhibitor Cohort
Prazo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If participant did not complete treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication).
Untreated bleed: If a bleed was untreated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication), it was considered as an untreated bleed.
Total bleeds: Treated bleeds + untreated bleeds.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Change From Baseline in Hemophilia Joint Health Score (HJHS) at Month 6: Non-Inhibitor Cohort
Prazo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score.
Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]).
Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg.
HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4).
The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in HJHS at Month 6: Inhibitor Cohort
Prazo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score.
Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]).
Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg.
HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4).
The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) Total Score and Physical Health Domain at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Prazo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia.
It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality.
All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Haem-A-QoL Total Score and Physical Health Domain at Month 6: Inhibitor Cohort, Participants >=17 Years
Prazo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia.
It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality.
All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Quality of Life Questionnaire for Children (Haemo-QoL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Prazo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia.
It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship.
All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Haemo-QoL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Prazo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia.
It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship.
All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Activities List (HAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Prazo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age).
The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in HAL Total Score at Month 6: Inhibitor Cohort, Participants >=17 Years
Prazo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age).
The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Pediatric Hemophilia Activities List (pedHAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Prazo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age).
The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in pedHAL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Prazo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age).
The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Patient Global Impression of Change-Hemophilia (PGIC-H) at Month 6: Non-Inhibitor Cohort
Prazo: Month 6
|
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
|
Month 6
|
|
PGIC-H at Month 6: Inhibitor Cohort
Prazo: Month 6
|
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
|
Month 6
|
|
Change From Baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Index and VAS Scores at Month 6: Non-Inhibitor Cohort
Prazo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS).
EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems).
Responses to 5 dimensions comprised health state index value.
E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it.
EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states.
The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in EQ-5D-5L Index and VAS Scores at Month 6: Inhibitor Cohort
Prazo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS).
EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems).
Responses to 5 dimensions comprised health state index value.
E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it.
EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states.
The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Pfizer CT.gov Call Center, Pfizer
Publicações e links úteis
Publicações Gerais
- Matino D, Acharya SS, Taylor CT, Sun P, Agathon D, Raje S, Gould T, Palladino A, Mahlangu J, Lissitchkov T, Todorova M, Chan A, Carcao M, Sun J, Yang R, Wu R, Jin C, Zeng X, Boban A, Bilic E, Frenzel L, Fung Chan GC, Kong Li C, Apte S, Choraria N, Chistolini A, Marchesini E, Peyvandi F, Fujii T, Matsushita T, Kaneda M, Lyu CJ, Park YS, Kim S, Martinez LV, Adrian JM, Wali Y, Al Khabori M, Kurtov I, Alzahrani H, Zaher G, Micic D, Miljic P, Kostic G, Vucic M, Djurdjevic P, Hidalgo OB, Porras JG, Jimenez-Yuste V, Calvo Villas JM, Lopez Fernandez MF, Albayrak C, Okan V, Balkan C, Sahin F, Antmen A, Unal E, Visweshwar N, Sharathkumar A, Kruse-Jarres R. Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial. Blood. 2026 Feb 26;147(9):920-931. doi: 10.1182/blood.2025031065.
- Matino D, Palladino A, Taylor CT, Hwang E, Raje S, Nayak S, McDonald R, Acharya SS, Mahlangu J, Jimenez-Yuste V, Choraria N, Yang R, Li CK, Al-Khabori M, Wali Y, Morales Adrian J, Park YS, Zulfikar OB, Teeter J. Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. Blood. 2025 Oct 2;146(14):1654-1663. doi: 10.1182/blood.2024027468.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Processos Patológicos
- Doenças Genéticas, Congênitas
- Doenças Hematológicas
- Distúrbios da Coagulação Sanguínea
- Distúrbios hemorrágicos
- Doenças Genéticas, Ligadas ao X
- Distúrbios da Coagulação Sanguínea, Herdados
- Distúrbios da Proteína de Coagulação
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Condições Patológicas, Sinais e Sintomas
- Doenças hemic e linfáticas
- Hemofilia A
- Hemorragia
- Hemofilia B
- Marstacimab
Outros números de identificação do estudo
- B7841005
- 2018-003660-31 (Número EudraCT)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .